GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Operating Cash Flow per Share

SELLAS Life Sciences Group (FRA:RXK3) Operating Cash Flow per Share : €-0.84 (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Operating Cash Flow per Share?

SELLAS Life Sciences Group's operating cash flow per share for the three months ended in Mar. 2024 was €-0.22. SELLAS Life Sciences Group's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.84.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 4.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 55.20% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 67.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for SELLAS Life Sciences Group's Operating Cash Flow per Share or its related term are showing as below:

FRA:RXK3' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 2   Med: 43.7   Max: 82.3
Current: 4.7

During the past 13 years, SELLAS Life Sciences Group's highest 3-Year average Operating Cash Flow per Share Growth Rate was 82.30% per year. The lowest was 2.00% per year. And the median was 43.70% per year.

FRA:RXK3's 3-Year OCF Growth Rate is ranked better than
51.74% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs FRA:RXK3: 4.70

SELLAS Life Sciences Group Operating Cash Flow per Share Historical Data

The historical data trend for SELLAS Life Sciences Group's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Operating Cash Flow per Share Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.21 -1.07 -1.49 -1.16 -1.04

SELLAS Life Sciences Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 -0.25 -0.23 -0.14 -0.22

Competitive Comparison of SELLAS Life Sciences Group's Operating Cash Flow per Share

For the Biotechnology subindustry, SELLAS Life Sciences Group's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Price-to-Operating-Cash-Flow falls into.



SELLAS Life Sciences Group Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

SELLAS Life Sciences Group's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-28.803/27.777
=-1.04

SELLAS Life Sciences Group's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-9.9/44.813
=-0.22

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SELLAS Life Sciences Group Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines